Insiders Are Spending Big: 15 Stocks Leading in March

6. Immunocore Holdings plc (NASDAQ:IMCR)

Total Value of Insider Purchases In March: $23.99 million

Market Capitalization: $1.44 billion

Immunocore is a commercial-stage biotechnology company that develops immunotherapies for cancer, infectious, and autoimmune diseases. Its key products include KIMMTRAK for metastatic uveal melanoma and various oncology and infectious disease treatments in clinical trials, such as tebentafusp, brenetafusp, and IMC-M113V for HIV. The biotech is based in Abingdon, UK.

For the fourth quarter and year ended December 31, 2024, the company reported net sales of $84.1 million and $310.2 million, respectively, arising from the sale of KIMMTRAK, of which $63.8 million and $226.7 million, respectively was in the United States. Net sales compare to $249.43 million in 2023. Net loss for the quarter and year ended December 31, 2024, was $23.8 million and $51.1 million, respectively, as compared to $19.7 million and $55.3 million, respectively, for the same periods in 2023.

In March, one insider acquired $23.99 million worth of Immunocore shares at an average price of $29.65 per share. Year-to-date, the stock is up 4.81%, trading at $30.92 per share. Over the past 12 months, Immunocore shares declined 50.84%.

Twelve analysts rate Immunocore stock as a “Buy,” with a 12-month price target of $63.00, indicating a potential upside of 119.4% from the last price, according to StockAnalysis.